Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
Across the street from MD Anderson, at Texas Children's Hospital, Fivecoat's then-nearly 1-year-old granddaughter Whitney was ...
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
I was diagnosed with acute myeloid leukemia, and the prognosis was not good. I was given just a few months to live. The ...
In8bio recently announced its financial results for the third quarter of 2024, highlighting significant advancements in its INB-100 program for Acute Myeloid Leukemia (AML). The company reported ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
James enjoys watching sports and helping gamblers win money. NBA referee Scott Wall was diagnosed with acute myeloid ...
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...